<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432022000200008</article-id>
<article-id pub-id-type="doi">10.7399/fh.13036</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Gestión farmacoterapéutica de los medicamentos de terapias avanzadas]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacotherapeutic management of advanced therapy medicinal products]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Poveda-Andrés]]></surname>
<given-names><![CDATA[José Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Caldes]]></surname>
<given-names><![CDATA[María José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carreras-Soler]]></surname>
<given-names><![CDATA[María José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Clopés-Estela]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Moreno]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Pellicer]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Giráldez-Quiroga]]></surname>
<given-names><![CDATA[Míriam]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Briz]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lozano-Blázquez]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Megías-Vericat]]></surname>
<given-names><![CDATA[Juan Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tordera-Baviera]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valero-García]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitari i Politècnic La Fe Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitari Vall D´Hebron Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospitalet de Llobregat Institut Català D'Oncología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario Virgen del Rocío Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Clínica Universitaria de Navarra Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Navarra ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Universitario Central de Asturias Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Oviedo Asturias]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<volume>46</volume>
<numero>2</numero>
<fpage>88</fpage>
<lpage>95</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432022000200008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432022000200008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432022000200008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los medicamentos de terapia avanzada han emergido en los últimos años como nuevas estrategias farmacoterapéuticas. En este contexto, los servicios de farmacia hospitalaria nos hemos tenido que adaptar al nuevo reto que ha supuesto su inclusión en nuestra cartera de servicios dentro del complejo proceso farmacoterapéutico en el que están inmersos los pacientes. Todas las actividades que se desarrollan en los servicios de farmacia hospitalaria cumplen con una base legal establecida en nuestra legislación y garantizan la calidad y seguridad tanto de los pacientes atendidos como de todos y cada uno de los medicamentos que se gestionan. Los medicamentos de terapia avanzada tienen unas características especiales a considerar que van desde las fases iniciales de selección y evaluación de los pacientes candidatos y su modelo de financiación, basado en riesgo compartido, hasta una fragilidad en su manipulación que requiere de una adecuada y adaptada formación del personal implicado en la logística para mantener su viabilidad, al necesitar unas condiciones de conservación, en ocasiones, a temperaturas de menos 180 ºC, en el caso de las células T con receptores quiméricos de antígenos. Además, la utilización clínica de los medicamentos de terapia avanzada ha necesitado de documentos de consenso de las sociedades científicas utilique pongan en valor el posicionamiento del farmacéutico hospitalario, como miembro indispensable dentro del equipo multidisciplinar asistencial, y que garanticen, como en cualquier otro medicamento, la trazabilidad, la correcta conservación y custodia y el seguimiento farmacoterapéutico asociado a una adecuada atención farmacéutica de nuestros pacientes, sin olvidar la importancia de la creciente investigación clínica, necesaria e imprescindible para una incorporación segura de nuevas dianas terapéuticas. Por todo ello, consideramos necesario el presente documento, en donde se ponen de manifiesto los retos o necesidades, desde el punto de vista farmacéutico, en cada una de las etapas o procesos a considerar en la utilización de los medicamentos de terapia avanzada dentro de nuestro amplio arsenal terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Advanced therapy medicinal products have emerged in recent years as new pharmacotherapeutic strategies. In this context, hospital pharmacy services have had to adapt to the new challenges posed by the inclusion of advanced therapies in their roster of services against the background of the complex pharmacotherapeutic process patients typically go through. All the activities carried out in the hospital pharmacy services must abide by the rules established in the Spanish legislation and ensure both the quality of the different drugs they manage and the safety of every single patient. Advanced therapy medicinal products are associated certain peculiarities, including the need to select and evaluate potential candidates to receive them; recourse to financing mechanisms based on risk sharing; and their extreme fragility, which means that the personnel in charge of handling them must be properly trained to maintain their viability and that special storage conditions, involving temperatures below 180 ºC in the case of chimeric antigen receptor T cell therapies, must be maintained. In addition, use of advanced therapy medicinal products in the clinical setting has made it necessary for scientific societies to produce consensus documents recognizing the pivotal role of hospital pharmacists as indispensable members of the multidisciplinary healthcare team and ensuring the same traceability, conservation, custody and pharmacotherapeutical monitoring standards imposed on other drugs to provide for adequate pharmaceutical care. Scientific societies have also highlighted the importance of intensifying clinical research, an essential requirement for the safe incorporation of new therapeutic targets. The present document is intended to describe the challenges pharmacists may face when using advanced therapy medicinal products at the different stages or processes in the patient&#8217;s clinical journey.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inmunoterapia celular adoptiva]]></kwd>
<kwd lng="es"><![CDATA[Terapia CAR-T]]></kwd>
<kwd lng="es"><![CDATA[Terapia génica]]></kwd>
<kwd lng="es"><![CDATA[Criopreservación]]></kwd>
<kwd lng="es"><![CDATA[Evaluación resultados pacientes]]></kwd>
<kwd lng="en"><![CDATA[Adoptive cellular immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[CAR-T cell therapy]]></kwd>
<kwd lng="en"><![CDATA[Gene therapy]]></kwd>
<kwd lng="en"><![CDATA[Cryopreservation]]></kwd>
<kwd lng="en"><![CDATA[Patient outcomes assessment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reglamento (CE) n.º 1394/2007 del Parlamento Europeo y del Consejo, de 13 de noviembre de 2007, sobre medicamentos de terapia avanzada y por el que se modifican la Directiva 2001/83/CE y el Reglamento (CE) n.º 726/2004]]></article-title>
<source><![CDATA[Diario Oficial de la Unión Europea]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamas-Díaz]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapias avanzadas]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Preguntas y respuestas sobre regulación de medicamentos de terapia avanzada]]></article-title>
<source><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estévez Álamo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Timón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Gómez-Platero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Doadrio Abad]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Velasco González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Mingo Ballesteros]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical trials of advanced therapy investigational medicinal products in Spain: preparing for the European clinical trials regulation]]></article-title>
<source><![CDATA[Cell &amp; Gene Therapy Insights]]></source>
<year>2019</year>
<volume>5</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1431-49</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guía de buenas prácticas de preparación de medicamentos en servicios de farmacia hospitalaria]]></article-title>
<source><![CDATA[Ministerio de Sanidad, Servicios Sociales e Igualdad]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eder]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wild]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Technology forecast: advanced therapies in late clinical research, EMA approval for clinical application via hospital exemption]]></article-title>
<source><![CDATA[J Market Access &amp; Health Policy]]></source>
<year>2019</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidelines on Good Clinical Practice specific to Advanced Therapy Medicinal Products]]></article-title>
<source><![CDATA[European Commission]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ley 14/1986, de 25 de abril, General de Sanidad]]></article-title>
<source><![CDATA[Boletín Oficial del Estado]]></source>
<year></year>
<numero>102</numero>
<issue>102</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Real Decreto 1/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garantías y uso racional de los medicamentos y productos sanitarios]]></article-title>
<source><![CDATA[Boletín Oficial del Estado n.º 177]]></source>
<year></year>
<numero>177</numero>
<issue>177</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Real Decreto 16/2012, de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones]]></article-title>
<source><![CDATA[Boletín Oficial del Estado]]></source>
<year>2012</year>
<numero>98</numero>
<issue>98</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Remuzat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Auquier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Toumi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced therapy medicinal products: current and future perspectives]]></article-title>
<source><![CDATA[J Market Access &amp; Health Policy]]></source>
<year>2016</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verter]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Silva Couto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bersenev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New trials of cell-based therapy surged in 2020, both because of and despite the pandemic]]></article-title>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Growth &amp; Resilience in Regenerative Medicine. Annual Report]]></article-title>
<source><![CDATA[Alliance for Regenerative Medicine]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[American Society of Gene + Cell Therapy]]></article-title>
<source><![CDATA[Clinical Trials Finder]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2020</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>311-20</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elsallab]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bravery]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abou-El-Enein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitigating deficiencies in evidence during assessments of advanced therapies: a comparative study with other biologicals]]></article-title>
<source><![CDATA[Mol Ther Methods Clin Dev]]></source>
<year>2020</year>
<volume>18</volume>
<page-range>269-79</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<collab>Committee for Advanced Therapies</collab>
<article-title xml:lang=""><![CDATA[Challenges with advanced therapy medicinal products and how to meet them]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2010</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>195-201</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seoane-Vázquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Shukla]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Monguio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Innovation and competition in advanced therapy medicinal products]]></article-title>
<source><![CDATA[EMBO Mol Med]]></source>
<year>2019</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrison]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kenston]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold]]></article-title>
<source><![CDATA[J Manag Care Spec Phar]]></source>
<year>2019</year>
<volume>25</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>793-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lloyd-Williams]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of economic evaluations of advanced therapy medicinal products]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2021</year>
<volume>87</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno Martínez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Vinent-Genestar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carreras Soler]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Funciones y responsabilidades del farmacéutico de hospital con los medicamentos CAR-T]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-31</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<collab>Sociedad Española de Farmacia Hospitalaria</collab>
<article-title xml:lang=""><![CDATA[Procedimiento de gestión de medicamentos CAR-T]]></article-title>
<source><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Pellicer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Caldes]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Poveda]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Logistics of the CAR-T medicines in a Hospital Pharmacy Service]]></article-title>
<source><![CDATA[European Journal of Clinical Pharmacy]]></source>
<year>2020</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-38</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[NTP 383: Riesgo en la utilización de gases licuados a baja temperatura]]></article-title>
<source><![CDATA[Instituto Nacional de Seguridad e Higiene en el Trabajo]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poveda Andrés]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Blázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Caldes]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[García Pellicer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacia Hospitalaria y Atención Farmacéutica con Terapias Avanzadas, módulo 4]]></article-title>
<source><![CDATA[Monografías de Farmacia Hospitalaria y de Atención Primaria]]></source>
<year>2020</year>
<page-range>76-106</page-range><publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Bayer Hispania]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<collab>Ministerio de Economía y Competitividad</collab>
<article-title xml:lang=""><![CDATA[Procedimiento de trabajo general para la manipulación de nitrógeno líquido]]></article-title>
<source><![CDATA[CSIC]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sesques]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrant]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Safar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wallet]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tordo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dhomps]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2020</year>
<volume>95</volume>
<page-range>1324-33</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yassine]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Iqbal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Murthy]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kharfan-Dabaja]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Chavez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials]]></article-title>
<source><![CDATA[Curr Res Transl Med]]></source>
<year>2020</year>
<volume>68</volume>
<page-range>159-70</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iacoboni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Villacampa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Cibrian]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bailén]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[López Corral]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma]]></article-title>
<source><![CDATA[Cancer Med]]></source>
<year>2021</year>
<volume>10</volume>
<page-range>3214-23</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuhnl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roddie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Cibrian]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Menne]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Linton]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lugthart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real&#8209;world data of high grade lymphoma patients treated with CD19 CAR-T in England]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2019</year>
<volume>134</volume>
<numero>suppl 1</numero>
<issue>suppl 1</issue>
<page-range>764-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jönsson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Michaels]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Towse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Von der Schulenburg]]></surname>
<given-names><![CDATA[J-MG]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>427-38</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrison]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Towse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Briggs]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Pouvourville]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grueger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mohr]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2013</year>
<volume>16</volume>
<page-range>703-19</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jørgensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kefalas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries]]></article-title>
<source><![CDATA[J Mark Access Health Policy]]></source>
<year>2020</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<collab>Center for International Blood &amp; Marrow Transplant Research</collab>
<article-title xml:lang=""><![CDATA[Current Uses of CAR T-cell Therapies in the US]]></article-title>
<source><![CDATA[Cellular Immunotherapy Data Resource (CIDR)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Registration of CAR-T Cellular therapies in EBMT Registry]]></article-title>
<source><![CDATA[European Society for Blood and Marrow Transplantation]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yakoub-Agha]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chabannon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bader]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Basak]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Bonig]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ciceri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2020</year>
<volume>105</volume>
<page-range>216-97</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Gouill]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bachy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Di Blasi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cartron]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Beauvais]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Le Bras]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies]]></article-title>
<source><![CDATA[EHA 2021]]></source>
<year>2021</year>
<numero>S216</numero>
<issue>S216</issue>
</nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="">
<source><![CDATA[Informe de seguimiento de la Dirección General de Cartera Común de Servicios del Sistema Nacional de Salud (SNS) y Farmacia sobre el Plan para el Abordaje de las Terapias Avanzadas en el SNS]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roig Izquierdo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prat Casanovas]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Gorgas Torner]]></surname>
<given-names><![CDATA[MQ]]></given-names>
</name>
<name>
<surname><![CDATA[Pontes García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Registro de pacientes y tratamientos de medicamentos hospitalarios en Cataluña: 10 años de datos clínicos]]></article-title>
<source><![CDATA[Medicina Clínica]]></source>
<year>2020</year>
<volume>15</volume>
<page-range>185-91</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Informes de utilización y de seguimiento de resultados. Programa de armonización farmacoterapéutica]]></article-title>
<source><![CDATA[Servicio Catalán de la Salud]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Directrices sobre normas de correcta fabricación específicas para Medicamentos de Terapia Avanzada]]></article-title>
<source><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petrich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marchese]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Storey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blind]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gene Replacement Therapy: A Primer for the Health-system Pharmacist]]></article-title>
<source><![CDATA[J Pharm Pract]]></source>
<year>2020</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>846-55</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Real Decreto 477/2014, de 13 de junio, por el que se regula la autorización de medicamentos de terapia avanzada de fabricación no industrial]]></article-title>
<source><![CDATA[Boletín Oficial del Estado]]></source>
<year>2014</year>
<numero>144</numero>
<issue>144</issue>
</nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Autorizaciones de uso de medicamentos de terapia avanzada concedidas por la AEMPS al amparo del Real Decreto 477/2014, de 13 de junio, por el que se regula la autorización de medicamentos de terapia avanzada de fabricación no industrial]]></article-title>
<source><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
